Clinical Competition Candidate
OFEV
OFEV carries substance and product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 41 months away. Active clinical competition may compress the generic entry window.
LOE window
41months
to latest listed patent expiry (December 7, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 8
Complexity score: 3/5
Clinical competition
Score: 4/5
Active trials linked: 255
Phase 2/3 trials: 121
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: NINTEDANIB ESYLATE
Applicant (NDA holder): BOEHRINGER INGELHEIM PHARMACEUTICALS INC
Confidence: High